What are your top takeaways from SGO 2025?

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy for patients with early-stage, intermediate-risk cervical carcinoma indicated that the addition of chemotherapy did not improve...

Many great studies were presented at SGO this year, and there is much to absorb!
An overall takeaway: Identification of appropriate biomarkers is fundamental in drug development for gynecologic malignancies, a strong theme at this year’s SGO.

Discussion of specific presentations:

Ovarian Cancer S...

The Scientific plenary: IMPACTful trials. There was, of course, an important presentation on the most recent updates for big trials such as KN-A18 with reports on OS2 and subgroup analysis. Immunotherapy is always a hot topic, and integration into the gynecological treatment algorithm is important t...